CPHI Logo

China Pharma Holdings, Inc. (CPHI) 

AMEX$0.2648
Market Cap
$5.04M
Sector
Healthcare
Industry
Drug Manufacturers—Specialty & Generic
Rank in Sector
528 of 919
Rank in Industry
27 of 56

CPHI Insider Trading Activity

CPHI Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$00–
Sells
$00–

Related Transactions

No records found

About China Pharma Holdings, Inc.

China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products primarily to hospitals and private retailers in the People's Republic of China. The company offers products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate and Ozagrel Sodium to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension. It also provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. In addition, the company offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Further, it provides Vitamin B6 injection; Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. The company offers its products through distributors, as well as through its network of 16 sales offices and approximately 1,000 sales representatives. China Pharma Holdings, Inc. was founded in 1993 and is based in Haikou, the People's Republic of China.

Insider Activity of China Pharma Holdings, Inc.

Over the last 12 months, insiders at China Pharma Holdings, Inc. have bought $0 and sold $0 worth of China Pharma Holdings, Inc. stock.

On average, over the past 5 years, insiders at China Pharma Holdings, Inc. have bought $0 and sold $0 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

List of Insider Buy and Sell Transactions, China Pharma Holdings, Inc.

2005-10-04SaleHALTER TIMOTHY PCEO, Pres, CFO, Chairman & Sec
1.83M
4.7382%
$0.10$182,817-34.98%
Total: 1

CPHI Institutional Investors: Active Positions

Increased Positions4+400%133,163+327.47%
Decreased Positions0company.decreased0company.decreased
New Positions2New36,842New
Sold Out Positions0Sold Out0Sold Out
Total Postitions5+400%173,827+327.47%

CPHI Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Two Sigma Securities, Llc$16.000.37%69,832+50,785+266.63%2024-12-31
Xtx Topco Ltd$16.000.35%67,123+45,536+210.94%2024-12-31
Ubs Group Ag$7.000.17%31,510+31,510New2024-12-31
Citigroup Inc$1.000.03%5,332+5,332New2024-12-31
First Community Trust Na$00%3000%2024-12-31

Financial Ratios

Summary
Comparison with Competitors

Analyst Recommendations

Analyst Price Targets

No data is available at this moment.
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.